These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 16371404)

  • 1. Low-density lipoprotein size and cardiovascular risk assessment.
    Rizzo M; Berneis K
    QJM; 2006 Jan; 99(1):1-14. PubMed ID: 16371404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The significance of low-density-lipoproteins size in vascular diseases.
    Rizzo M; Berneis K; Corrado E; Novo S
    Int Angiol; 2006 Mar; 25(1):4-9. PubMed ID: 16520717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Who needs to care about small, dense low-density lipoproteins?
    Rizzo M; Berneis K
    Int J Clin Pract; 2007 Nov; 61(11):1949-56. PubMed ID: 17935554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein size and cardiovascular prevention.
    Rizzo M; Berneis K
    Eur J Intern Med; 2006 Mar; 17(2):77-80. PubMed ID: 16490681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should we measure routinely the LDL peak particle size?
    Rizzo M; Berneis K
    Int J Cardiol; 2006 Feb; 107(2):166-70. PubMed ID: 16412793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small, dense low-density-lipoproteins and the metabolic syndrome.
    Rizzo M; Berneis K
    Diabetes Metab Res Rev; 2007 Jan; 23(1):14-20. PubMed ID: 17080469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects.
    Lamarche B; Lemieux I; Després JP
    Diabetes Metab; 1999 Sep; 25(3):199-211. PubMed ID: 10499189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy.
    Rosenson RS
    Am Heart J; 2006 Mar; 151(3):556-63. PubMed ID: 16504615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipids in type 2 diabetes.
    Laakso M
    Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents.
    Dupuy AM; Carrière I; Scali J; Cristol JP; Ritchie K; Dartigues JF; Gambert P; Ancelin ML
    Climacteric; 2008 Feb; 11(1):74-83. PubMed ID: 18202967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes.
    Rizzo M; Rini GB; Berneis K
    Exp Clin Endocrinol Diabetes; 2007 Sep; 115(8):477-82. PubMed ID: 17853329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small dense low-density lipoprotein in renal transplant recipients: a potential target for prevention of cardiovascular complications?
    Badiou S; Garrigue V; Dupuy AM; Chong G; Cristol JP; Mourad G
    Transplant Proc; 2006 Sep; 38(7):2314-6. PubMed ID: 16980076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of low-density lipoprotein (LDL) particle size to thyroid function status in Koreans.
    Kim CS; Kang JG; Lee SJ; Ihm SH; Yoo HJ; Nam JS; Ahn CW; Kim KR
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):130-6. PubMed ID: 19178521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.